BridgeMD
Visugromab in Cachexia International Trial
EU CTIS ID: 2025-523533-25-00
What this study is testing
To investigate the efficacy of visugromab treatment, at various doses, in participants with cancer-associated cachexia
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Male and female participants aged ≥ 18 years at screening
- 2. Weight loss
- 3. Advanced cancer
- 4. Other protocol-defined criteria apply
You likely can't join if
- 1. Participation in another interventional clinical trial, receipt of any investigational therapy or use of any investigational device within 4 weeks prior to screening and between screening and the first dose of investigational product
- 2. Other protocol-defined criteria apply
The study team makes the final eligibility decision.
Where it's taking place
- Serbia
- Australia
- Canada
- Turkey
- Korea, Republic of
- Georgia
- Switzerland
- United States
- United Kingdom
- Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Serbia; Australia; Canada; Turkey; Korea, Republic of; Georgia and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.